Court Vacates Temporary Restraining Order, Denies Amylin's Request for Preliminary Injunction
INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals for a preliminary injunction that sought to impose restrictions on the Lilly Diabetes sales force and other relief. Amylin recently filed litigation involving the two companies' diabetes collaboration agreement.
"We are pleased with the Court's decision to vacate the temporary restraining order and deny Amylin's request for a preliminary injunction," said Robert A. Armitage, senior vice president and general counsel for Lilly "We have complied with our contractual obligations under our agreements with Amylin, and done so in a manner fully consistent with all applicable laws. We believe that Amylin's allegations against Lilly are entirely without merit and we fully expect to prevail in this litigation."
Enrique Conterno, president of Lilly Diabetes, said, "We are committed to offering a broad range of treatment options, including important new therapies, to people with diabetes and their health care providers. There is more work to be done, and we will continue to work hand in hand with all of our diabetes partners to achieve better outcomes for patients."
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY
This press release contains forward-looking statements about our alliance with Amylin, and it reflects Lilly's current beliefs. There are substantial risks and uncertainties in the process of drug development and commercialization. Further, we cannot predict the outcome of any litigation with Amylin or its effect on our collaboration. For further discussion of risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
SOURCE Eli Lilly and Company